PMS50 Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study  by Sieper, J. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A227 
 
 
tolerance if the benefits are changed. However, DCE seems to be more sensitive 
for a change in benefits and risks while the MAR estimates obtained through 
BWS have considerably lower uncertainty than DCE.  
 
PMS50  
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OBJECTIVES: RAPID-axSpA (NCT01087762) investigated the impact of 
certolizumab pegol (CZP) on patient reported outcomes (PRO) in axial 
spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-
radiographic axSpA (nr-axSpA, axSpA with no definitive sacroiliitis on X-ray). 
METHODS: The ongoing 158-week (Wk) RAPID-axSpA trial was double blind and 
placebo-controlled to Wk24. Recruited patients had adult-onset active axSpA, 
including AS and nr-axSpA. Patients were randomized 1:1:1 to placebo, or 400mg 
CZP at Wk0, two and four followed by either 200mg CZP every two weeks (Q2W) 
or 400mg CZP every four weeks (Q4W). PRO endpoints included, physical 
function (BASFI), total spinal pain, daily pain diary to Wk4, fatigue (from 
BASDAI), Ankylosing Spondylitis Quality of Life (AsQoL), Sleep Problems Index II 
domain of the MOS Sleep scale, and SF-36. Change from baseline in PRO was 
analyzed in full analysis set with LOCF imputation. RESULTS: A total of 325 
patients were randomized. Baseline characteristics were similar between groups. 
Compared to placebo, improvements at Wk24 in CZP 200mg Q2W and 400mg 
Q4W treated groups were observed in pain (-1.3 vs. -3.3 and -3.2), fatigue (-0.9 vs. 
-2.6 and -2.8), BASFI (-0.5 vs. -2.4 and -2.2) and AsQoL (-1.7 vs. -5.1 and -5.1). 
Improvements were seen from Wk1, and in spinal pain from day 2. CZP-treated 
patients also had greater improvements in sleep, and SF-36 components and 
domains. More CZP patients reached population norms for SF-36. CZP impact on 
pain, fatigue and AsQoL in AS and nr-axSpA patients was similar. Relative to 
placebo, CZP-treated nr-axSpA patients demonstrated greater improvements in 
BASFI and sleep compared to AS, and were more likely to reach population 
norms for SF-36. CONCLUSIONS: Both dosing regimens of CZP rapidly improved 
all PRO including pain, fatigue, physical function and QoL of axSpA, in both AS 
and nr-axSpA patients.  
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OBJECTIVES: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient reported outcomes (PRO) in psoriatic arthritis (PsA), as 
investigated in RAPID-PsA (NCT01087788). METHODS: The ongoing 158 week 
(Wk) RAPID-PsA trial is double blind and placebo-controlled to Wk24. Recruited 
patients had active PsA and had failed ≥1 DMARD. Patients could have received 1 
previous anti-TNF. Patients were randomized 1:1:1 to placebo, or 400mg CZP  
at Wk 0, 2 and 4 (loading dose) followed by either 200mg CZP every 2 weeks 
(Q2W) or 400mg CZP every 4 weeks (Q4W). PRO measures evaluated: fatigue 
assessment scale (FAS), patient assessment of pain (VAS), health assessment 
questionnaire-disability index (HAQ-DI), SF-36, PsAQoL, and the Dermatology 
Life Quality Index (DLQI). Change from baseline for PRO was analyzed for  
the randomized population, with LOCF imputation. RESULTS: A total of 409 
patients were randomized. 20% of patients had received a prior anti-TNF. 
Baseline demographics were similar between groups. From baseline to Wk24, 
differences in pain (-11.2 vs. -28.6 and -28.4), fatigue (-0.6 vs. -2.2 and -1.9), HAQ-
DI (-0.19 vs. -0.54 and -0.46), SF-36 physical component summary (2.14 vs. 8.43 
and 7.58) and mental component summary (0.73 vs 5.49 and 3.49), PsAQoL (-1.27 
vs. -4.43 and -3.30), and DLQI (-1.4 vs. -6.3 and -5.2) were observed in placebo vs. 
CZP 200mg Q2W and 400mg Q4W arms (p<0.001). Differences were observed 
from Wk1 and were irrespective of prior anti-TNF exposure. More patients on 
CZP reached SF-36 general population norms than placebo patients. 
CONCLUSIONS: CZP effectively improved multiple PROs in PsA patients across 
many disease facets. The benefits of CZP treatment on physical and emotional 
components of HRQoL were seen across generic, PsA-specific and dermatology-
specific measures. These benefits were seen in patients regardless of prior anti-
TNF exposure.  
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OBJECTIVES: To determine the impact of improvements in skin and 
musculoskeletal components on quality of life (QoL), we studied patients with 
both moderate-to-severe psoriasis and psoriatic arthritis (PsA) treated with 
etanercept (ETN). METHODS: Ad hoc analyses were performed on pooled data 
from the PRESTA trial in which patients were randomized to ETN 50 mg once 
weekly (QW) for 12 weeks or ETN 50 mg twice weekly for 12 weeks, followed by 
ETN 50 mg QW for 12 weeks. Dermatologists evaluated skin disease using the 
Psoriasis Activity and Severity Index (PASI) endpoints PASI50 (50% improvement) 
and PASI75 (75% improvement). Rheumatologists evaluated arthritis using the 
American College of Rheumatology (ACR) endpoints of ACR20 and ACR50 (≥20% 
and ≥50% improvement in ACR core criteria, respectively). To measure QoL, 
patients completed the EuroQoL-5 Dimension (EQ-5D) utility (scale 0–1, higher 
scores=better QoL, minimal important difference [MID]=0.05) and Visual Analog 
Scale (VAS; scale 0–100, higher scores=better health state, MID=5) questionnaire. 
RESULTS: Improvements from baseline at week 24 in EQ-5D utility and VAS 
scores for patients achieving ACR50 but not PASI75 (n=89) were significantly and 
clinically meaningfully greater than patients achieving PASI75 but not ACR50 
(n=193; EQ-5D utility Δ=0.327 vs. 0.199, P<0.001; EQ-5D VAS Δ=23.7 vs. 15.1, 
P=0.002). Similarly, improvements for patients achieving ACR20 but not PASI50 
(n=55) were significantly greater than those achieving PASI50 but not ACR20 
(n=163; EQ-5D utility Δ=0.385 vs. 0.134, P<0.001; EQ-5D VAS Δ=19.3 vs. 10.4, 
P=0.005). CONCLUSIONS: Patients with both moderate-to-severe psoriasis and 
PsA showing greater improvements in arthritis than psoriasis reported more QoL 
gains compared with those with greater improvements in psoriasis than 
arthritis. Although the ACR response and PASI measures are formed of different 
components, the magnitude of the QoL gain with improvement in arthritis 
shows that the arthritis component of psoriatic disease contributes significantly 
to reduced QoL.  
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OBJECTIVES: To assess the physical component score (PCS), mental component 
score (MCS), and EuroQol (EQ5D) score of RA and non-RA patients. METHODS: 
Retrospective analysis of civilian non-institutionalized Medical Expenditures 
Panel Survey (MEPS) data for the year 2006. 20,434 respondents had positive 
weight, had complete information, and who were atleast 18 years were included 
in the analysis. Clinical Classification Code 202 identified RA respondents. RA 
and Non-RA respondents were matched on age, gender, race, education, marital 
status, income, region, insurance, and comorbidity index score. Since the MEPS 
2006 consists of only PCS and MCS, a mapping algorithm was used to derive EQ-
5D score. Proc surveyfreq, and proc surveymeans to describe the demographic 
characteristics. T-tests were used to measure statistical differences in QOL 
scores between the 2 groups. RESULTS: Among adults with RA, 86.75% were 
whites with mean (SE) age of 59.83 (1.18) years and 80% were females. The mean 
(SE) PCS scores for the RA and Non-RA group was 34.25 (1.35) and 45.46 (1.30). 
The mean (SE) MCS scores for the RA and Non-RA group was 47.49 (1.09) and 
51.14 (0.86). The mean (SE) EQ-5D index score for the RA and Non-RA groups was 
0.74 (0.02) and 0.86 (0.01). The results were significant at an apriori alpha value of 
0.05. CONCLUSIONS: Since the disease conditions were self-reported and 
institutionalized persons were not included, the true prevalence of RA may be 
underestimated. All QOL scores for RA patients were lower in the 2006 MEPS data 
indicating that respondents with RA have reduced QOL. RA significantly impairs 
QOL in the U.S. population. The study trengthens the importance of treating RA. 
This study did not differentiate QOL by severity of RA. RA-specific QOL measures 
were unavailable in MEPS.  
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OBJECTIVES: Examine impact of ustekinumab treatment on general &disease-
specific patient reported outcomes (PROs) of patients with active PsA using 
PSUMMIT1 data. METHODS: Adult PsA patients (n=615) with active disease 
despite DMARD&/or NSAID therapy were randomized to ustekinumab 45mg, 
90mg, or PBO at wks0, 4, &q12wks, thereafter. Patients treated with prior anti-
TNF agents were excluded. At wk16, patients with <5% improvement in SJC/TJC 
entered blinded EE (PBO→ustekinumab 45mg; ustekinumab 45mg→90mg; 
90mg→90mg). PROs were measured with HAQ, DLQI, SF-36, &VAS for impact of 
PsA on work productivity (0-10), patient assessment of pain (0-10)& disease 
activity (0-10). ANOVA on van der Waerden normal scores was used for 
continuous variables & chi-square or the Cochran-Mantel-Haenszel (CMH) test 
for binary variables between groups. RESULTS: Baseline PRO measures indicated 
the study population had severe physical disability& impaired HRQoL, with 
mean HAQ score of 1.25 &mean DLQI score of ≥10. At wk24, greater 
improvements in: HAQ (0.31&0.4 vs. 0.1, P<0.001), DLQI (6.6&7.5 vs. 1.4, P<0.001), 
SF-36 PCS (4.9 &6.2 vs. 1.4, P<0.001)& MCS (3.4&4.8 vs. 1.5, p<0.01 90 mg only) 
were observed in ustekinumab 45mg &90mg groups vs PBO, respectively. 
Proportions of patients who achieved clinical meaningful improvements in HAQ 
≥0.3 (47.8% &47.5% vs. 28.2%, P<0.001), DLQI ≥5 (58.6% &63.1% vs. 32.9%, P<0.001), 
&SF-36 PCS ≥5(46.5% &53.3% vs. 26.0%, P<0.001) &MCS ≥5(37.0% &47.7% vs. 33.7%, 
p<0.01 90mg only) were greater in ustekinumab 45mg &90mg group vs PBO, 
